Latiglutenase
- Generic Name
- Latiglutenase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1360452-96-5
- Unique Ingredient Identifier
- 090PL12YZJ
- Indication
Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous) and autoimmune diseases such as celiac disease.
- Associated Conditions
- -
- Associated Therapies
- -
Entero signs Letter of Intent to license and commercialize remote patient and machine vision
Entero Therapeutics to exclusively license Data Vault's QOLPOM and FotoDigm software for GI clinical trials, with plans to secure up to $3 million in strategic investment. The deal aims to improve clinical trial compliance and outcomes, leveraging Data Vault's technology for Entero's phase 3 latiglutenase trial for celiac disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath